A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Osteosarcoma; Sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 16 Aug 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Aug 2019.
- 16 Aug 2016 Status changed from not yet recruiting to recruiting.
- 08 Jul 2016 New trial record